Eli Lilly and Boehringer Ingelheim’s Jardiance stays on its heart failure winning streak—this time in acute patients
Three months after earning an approval to treat chronic heart failure with their SGLT2 inhibitor Jardiance, Eli Lilly and Boehringer Ingelheim have posted new data th...
Continue Reading →
